company background image
ANAB

AnaptysBio NasdaqGS:ANAB Stock Report

Last Price

US$23.12

Market Cap

US$651.7m

7D

7.8%

1Y

-12.6%

Updated

24 Jun, 2022

Data

Company Financials +
ANAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANAB Stock Overview

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

AnaptysBio Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for AnaptysBio
Historical stock prices
Current Share PriceUS$23.12
52 Week HighUS$37.89
52 Week LowUS$18.20
Beta0.19
1 Month Change20.48%
3 Month Change-8.51%
1 Year Change-12.56%
3 Year Change-59.02%
5 Year Change-3.39%
Change since IPO36.00%

Recent News & Updates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Today is shaping up negative for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...

Shareholder Returns

ANABUS BiotechsUS Market
7D7.8%11.9%4.0%
1Y-12.6%-25.1%-20.5%

Return vs Industry: ANAB exceeded the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: ANAB exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is ANAB's price volatile compared to industry and market?
ANAB volatility
ANAB Average Weekly Movement9.6%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: ANAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ANAB's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005102Dan Fagahttps://www.anaptysbio.com

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

AnaptysBio Fundamentals Summary

How do AnaptysBio's earnings and revenue compare to its market cap?
ANAB fundamental statistics
Market CapUS$651.66m
Earnings (TTM)-US$75.89m
Revenue (TTM)US$52.90m

12.3x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANAB income statement (TTM)
RevenueUS$52.90m
Cost of RevenueUS$96.83m
Gross Profit-US$43.93m
Other ExpensesUS$31.96m
Earnings-US$75.89m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.69
Gross Margin-83.04%
Net Profit Margin-143.46%
Debt/Equity Ratio0%

How did ANAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ANAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANAB?

Other financial metrics that can be useful for relative valuation.

ANAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.2x
Enterprise Value/EBITDA-2.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ANAB's PS Ratio compare to its peers?

ANAB PS Ratio vs Peers
The above table shows the PS ratio for ANAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average49.1x

Price-To-Sales vs Peers: ANAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the peer average (49.1x).


Price to Earnings Ratio vs Industry

How does ANAB's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: ANAB is good value based on its Price-To-Sales Ratio (12.3x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is ANAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.3x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: ANAB is expensive based on its Price-To-Sales Ratio (12.3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).


Share Price vs Fair Value

What is the Fair Price of ANAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANAB's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANAB's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is AnaptysBio forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


0.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANAB's revenue (17.7% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ANAB's revenue (17.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANAB is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has AnaptysBio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-5.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANAB is currently unprofitable.

Growing Profit Margin: ANAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANAB is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare ANAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ANAB has a negative Return on Equity (-22.94%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is AnaptysBio's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ANAB's short term assets ($512.4M) exceed its short term liabilities ($19.8M).

Long Term Liabilities: ANAB's short term assets ($512.4M) exceed its long term liabilities ($274.6M).


Debt to Equity History and Analysis

Debt Level: ANAB is debt free.

Reducing Debt: ANAB has no debt compared to 5 years ago when its debt to equity ratio was 12.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANAB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ANAB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.3% each year


Discover healthy companies

Dividend

What is AnaptysBio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Dan Faga (41 yo)

0.25

Tenure

US$309,729

Compensation

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and serves as Interim President and Chief Ex...


Leadership Team

Experienced Management: ANAB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: ANAB's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

AnaptysBio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AnaptysBio, Inc.
  • Ticker: ANAB
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$651.662m
  • Shares outstanding: 28.19m
  • Website: https://www.anaptysbio.com

Number of Employees


Location

  • AnaptysBio, Inc.
  • 10770 Wateridge Circle
  • Suite 210
  • San Diego
  • California
  • 92121-5801
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.